Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOGAN: PK of Budesonide/Albuterol (PT027) vs Components
NCT03772223Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2019
- Primary completion
- May 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of salbutamol + budesonide in asthma (6 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Curve at Day 2, Area Under the Curve from time 0 to the last measurable concentration at Day 2 and 1 more. Started Jan 2019; status: completed.
02
Drugs
salbutamol + budesonide
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03772223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03772223.